In the last trading session, 1.06 million shares of the Aldeyra Therapeutics Inc (NASDAQ:ALDX) were traded, and its beta was 1.52. Most recently the company’s share price was $3.55, and it changed around $0.28 or 8.56% from the last close, which brings the market valuation of the company to $209.09M. ALDX currently trades at a discount to its 52-week high of $11.97, offering almost -237.18% off that amount. The share price’s 52-week low was $1.42, which indicates that the current value has risen by an impressive 60.0% since then. We note from Aldeyra Therapeutics Inc’s average daily trading volume that its 10-day average is 0.42 million shares, with the 3-month average coming to 497.84K.
Aldeyra Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ALDX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Aldeyra Therapeutics Inc is expected to report earnings per share of -$0.12 for the current quarter.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Instantly ALDX has showed a green trend with a performance of 8.56% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 1.14% year-to-date, but still up 23.26% over the last five days. On the other hand, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is -15.88% down in the 30-day period. We can see from the shorts that 1.83 million shares have been sold at a short interest cover period of 3.26 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 64.5% from its current value. Analyst projections state that ALDX is forecast to be at a low of $10 and a high of $10.
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
Aldeyra Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -46.86 percent over the past six months and at a 59.38% annual growth rate that is well above the industry average of 8.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 55.60% in revenue this quarter, and will report an increase of 6.70% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.70%.
ALDX Dividends
Aldeyra Therapeutics Inc’s next quarterly earnings report is expected to be released around May 02 and May 06.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.01% of Aldeyra Therapeutics Inc shares, and 60.64% of them are in the hands of institutional investors. The stock currently has a share float of 61.89%. Aldeyra Therapeutics Inc stock is held by 140 institutions, with Perceptive Advisors Llc being the largest institutional investor. By Jun 29, 2023, it held 19.37% of the shares, which is about 11.35 million shares worth $95.23 million.
Blackrock Inc., with 5.51% or 3.23 million shares worth $27.1 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Aug 30, 2023. The former held 2.13 million shares worth $15.91 million, making up 3.64% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.7 million shares worth around $14.24 million, which represents about 2.90% of the total shares outstanding.
